TLSA
Income statement / Annual
Last year (2025), Tiziana Life Sciences Ltd's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Tiziana Life Sciences Ltd's net income was -$18.43 M.
See Tiziana Life Sciences Ltd,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$14.59 M
|
$0.00
|
$0.00
|
$250.04 K
|
$16.00 K
|
$10.68 K
|
$8.79 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
-$14.59 M
|
$0.00
|
$0.00
|
-$250.04 K
|
-$16.00 K
|
-$10.68 K
|
-$8.79 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$10.28 M
|
$5.23 M
|
$8.11 M
|
$0.00
|
$17.82 M
|
$8.15 M
|
$3.73 M
|
$5.50 M
|
$4.67 M
|
$2.96 M
|
| General & Administrative Expenses |
$10.85 M
|
$10.57 M
|
$9.87 M
|
$0.00
|
$1.15 M
|
$17.97 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.85 M
|
$10.57 M
|
$9.87 M
|
$0.00
|
$1.15 M
|
$17.97 M
|
$5.79 M
|
$4.64 M
|
$0.00
|
$4.33 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$17.96 M
|
$12.00 M
|
-$17.55 K
|
-$228.20 K
|
$3.57 M
|
$0.00
|
| Operating Expenses |
$21.13 M
|
$15.79 M
|
$17.98 M
|
$0.00
|
$36.93 M
|
$38.12 M
|
$9.50 M
|
$9.91 M
|
$8.25 M
|
$7.29 M
|
| Cost And Expenses |
$21.13 M
|
$15.79 M
|
$17.98 M
|
$14.59 M
|
$36.93 M
|
$38.12 M
|
$9.96 M
|
$9.91 M
|
$8.25 M
|
$7.29 M
|
| Interest Income |
$19.00 K
|
$814.00 K
|
$1.15 M
|
$0.00
|
$0.00
|
$10.88 K
|
$1.28 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$18.00 K
|
$6.00 K
|
$10.00 K
|
$7.00 K
|
$237.41 K
|
$435.28 K
|
$93.57 K
|
$11.98 K
|
$8.74 K
|
$9.89 K
|
| Depreciation & Amortization |
$234.00 K
|
$124.00 K
|
$96.00 K
|
$51.00 K
|
$141.00 K
|
$89.76 K
|
$250.04 K
|
$16.00 K
|
$10.94 K
|
$8.10 K
|
| EBITDA |
-$18.18 M |
-$16.62 M |
-$17.14 M |
-$15.34 M |
-$35.58 M |
-$37.97 M |
-$9.71 M |
-$9.89 M |
-$8.24 M |
-$7.28 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.70 M
|
-$952.00 K
|
$742.00 K
|
-$811.00 K
|
$967.18 K
|
-$424.40 K
|
-$93.57 K
|
-$12.64 K
|
-$9.00 K
|
-$9.00 K
|
| Income Before Tax |
-$18.43 M
|
-$16.75 M
|
-$17.24 M
|
-$15.40 M
|
-$35.96 M
|
-$38.55 M
|
-$10.06 M
|
-$9.92 M
|
-$8.26 M
|
-$7.30 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$4.88 M
|
$449.00 K
|
$0.00
|
-$4.37 M
|
-$3.00 M
|
-$692.16 K
|
-$1.94 M
|
-$1.49 M
|
-$89.00 K
|
| Net Income |
-$18.43 M
|
-$11.86 M
|
-$17.69 M
|
-$15.40 M
|
-$31.59 M
|
-$35.54 M
|
-$9.36 M
|
-$7.98 M
|
-$6.77 M
|
-$7.21 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.16 |
-0.11 |
-0.17 |
-0.15 |
-0.32 |
-0.37 |
-0.0686 |
-0.0585 |
-0.0579 |
-0.0677 |
| EPS Diluted |
-0.16 |
-0.11 |
-0.17 |
-0.15 |
-0.32 |
-0.37 |
-0.0686 |
-0.0585 |
-0.0579 |
-0.0677 |
| Weighted Average Shares Out |
$118.28 M
|
$106.67 M
|
$102.47 M
|
$101.53 M
|
$97.93 M
|
$97.31 M
|
$136.48 M
|
$136.48 M
|
$116.98 M
|
$106.40 M
|
| Weighted Average Shares Out Diluted |
$118.28 M
|
$106.67 M
|
$102.47 M
|
$101.53 M
|
$97.93 M
|
$97.31 M
|
$136.48 M
|
$136.48 M
|
$116.98 M
|
$106.40 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
